...
首页> 外文期刊>Neuromolecular medicine >CSF sAPP alpha and sAPP beta levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis
【24h】

CSF sAPP alpha and sAPP beta levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis

机译:Alzheimer疾病的CSF SAPPα和SAPPβ水平和多种其他神经变性疾病:网络META分析

获取原文
获取原文并翻译 | 示例

摘要

The soluble amyloid protein procurer alpha (sAPP alpha) and beta (sAPP beta) have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) and multiple other neurodegenerative diseases, but have failed to meet expectations with their often discordant and even contradictory findings to date. The aim of the study was to systematically explore this issue. Cochrane Library, PubMed, and CNKI were systematically searched without language or date restrictions. This network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and also adhered to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. Twenty studies, comprising ten groups, were eligible and included. Overall, 19 eligible studies with 1634 patients contributed to the analysis of CSF sAPP alpha levels and 16 eligible studies with 1684 patients contributed to the analysis of CSF sAPP beta levels. CSF sAPP beta levels are significantly higher in AD than in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP); higher in Control than in Depression, CBS and PSP; higher in Parkinson's disease dementia (PDD) than in CBS and PSP; higher in mild cognitive impairment progressed to AD dementia during the follow-up period (pMCI) than in Depression and PSP; higher in stable mild cognitive impairment (sMCI) than in Depression. With regard to CSF sAPP alpha levels, there were no significant difference among groups. However, surprisingly, the resultant rankings graphically showed that pMCI populations have the highest levels of CSF sAPP alpha and sAPP beta. Furthermore, it seemed there was a positive correlation between CSF sAPP alpha and sAPP beta levels. The measurement of CSF sAPP alpha and sAPP beta levels may provide an alternative method for the diagnosis of early-stage AD, pMCI, which is conducive to preventive therapy.
机译:可溶性淀粉样蛋白丙酮α(SAPPα)和β(SAPPβ)已被假定为对阿尔茨海默病(AD)和多种其他神经退行性疾病的有前途的新脑脊液(CSF)生物标志物,但未能满足其经常不和谐的期望甚至达到矛盾的结果迄今为止。该研究的目的是系统地探索这个问题。没有语言或日期限制,系统地搜索了Cochrane图书馆,PubMed和CNKI。该网络元分析遵循了系统评价和荟萃分析(PRISMA)指南的首选报告项目,并遵守流行病学的观察研究的荟萃分析(驼鹿)指导。包括十组的二十项研究符合条件并包括在内。总体而言,19名符合条件的研究有1634名患者的患者促进了CSF SAPPα水平的分析和16名符合条件的研究,1684名患者有助于分析CSF SAPPβ水平。 AD中的CSFSAPPβ水平明显高于皮质缺鼠综合征(CBS)和进步性激脑麻痹(PSP);控制越高,抑郁症,CBS和PSP;帕金森病痴呆(PDD)高于CBS和PSP;在随访期间(PMCI)期间,轻度认知障碍的温和认知障碍更高,而不是抑郁症和PSP;在稳定的轻度认知障碍(SMCI)中更高,而不是抑郁症。关于CSF SAPPα水平,群体之间没有显着差异。然而,令人惊讶的是,图示的所得排名表明,PMCi群体具有最高水平的CSFSAPPα和SAPPβ。此外,似乎CSF SAPP alpha和SAPPβ水平之间存在正相关性。 CSF SAPPα和SAPPβ水平的测量可以提供诊断早期广告,PMCI的替代方法,这有利于预防治疗。

著录项

  • 来源
    《Neuromolecular medicine 》 |2020年第1期| 共11页
  • 作者单位

    Second Hosp Anhui Med Univ Dept Lab Med . 678 Furong Rd Hefei Anhui Peoples R China;

    Second Hosp Anhui Med Univ Dept Gen Surg . 678 Furong Rd Hefei Anhui Peoples R China;

    Second Hosp Anhui Med Univ Dept Lab Med . 678 Furong Rd Hefei Anhui Peoples R China;

    Second Hosp Anhui Med Univ Dept Lab Med . 678 Furong Rd Hefei Anhui Peoples R China;

    Anhui Med Univ Sch Publ Hlth Dept Clin Lab Med . 81 Meishan Rd Hefei Anhui Peoples R China;

    Second Hosp Anhui Med Univ Dept Lab Med . 678 Furong Rd Hefei Anhui Peoples R China;

    Second Hosp Anhui Med Univ Dept Lab Med . 678 Furong Rd Hefei Anhui Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学 ;
  • 关键词

    Neurodegenerative diseases; Alzheimer's disease; sAPP alpha; sAPP beta; Network meta-analysis;

    机译:神经退行性疾病;阿尔茨海默病;SAPP alpha;SAPP BETA;网络元分析;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号